An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Jyoti Wadhwa ( Moderator ) ,Dr Atul Sharma ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Srujna Joga ( Expert Panel )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

In this webinar, a detailed discussion is done on CROWN trial update: Optimizing 1st-line ALK+ mNSCLC management.

Speakers : Dr Srujna Joga ( Expert Panel ) ,Dr AP Dubey ( Expert Panel ) ,Dr Atul Sharma ( Expert Panel ) ,Dr Jyoti Wadhwa ( Moderator )

Efficient Management of First line ALK-rearranged NSCLC

In this webinar, a detailed discussion is done on the efficient management of first line ALK rearranged NSCLC.

Speakers : Dr B K ,Dr Abhishek Kakroo ,Dr Jogamaya Pattnaik

Efficient Management of First line ALK-rearranged NSCLC - Part V

Explore optimal first-line strategies for ALK-rearranged NSCLC to enhance survival and manage resistance.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part IV

Explore optimal first-line strategies and targeted therapies for managing ALK-rearranged non-small cell lung cancer.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part III

Explore optimal first-line strategies for managing ALK-rearranged NSCLC with advanced targeted therapies and clinical insights.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part II

Discover effective first-line strategies for managing ALK-rearranged NSCLC using targeted therapies and personalized treatment approaches.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti

Efficient Management of First line ALK-rearranged NSCLC - Part VI

In this webinar, a detailed discussion is done on the efficient management of first line ALK rearranged NSCLC.

Speakers : Dr Jogamaya Pattnaik

Efficient Management of First line ALK-rearranged NSCLC - Part VII

Explore first-line management strategies and targeted therapies for ALK-rearranged NSCLC to optimize patient outcomes.

Speakers : Dr Jogamaya Pattnaik ,Dr Abhishek Kakroo ,Dr B K Smruti


Recommended News For You

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

Resection for Early Liver Cancer Tied to Improved Survival.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

No increased risk of childhood cancer near UK nuclear sites, study finds

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

Recommended Articles For You

Exploring The Causes and Consequences of Low Transferrin Saturation 

HPV and Immunotherapy in Cancer Survivorship: National Cancer Survivors Day Review 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

The Miracle of Tenecteplase: How This Drug Is Saving Lives 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

3.

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?

1.

Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence

2.

The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025

3.

Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning

4.

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA

5.

How to Prevent Tumor Lysis Syndrome in Cancer Patients

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

2.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

3.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

5.

Navigating the Complexities of Ph Negative ALL - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot